Thoratec Seeks Less Invasive VAD Access With Apica Acquisition
This article was originally published in The Gray Sheet
Executive Summary
The completed deal calls for $35 million up front and $40 million in future clinical and sales milestones. Apica is developing systems to assist transapical surgical access for ventricular assist devices and transcatheter valve replacements.